Fragmento

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection: A systematic review and meta-analysis Manzano-Robleda MC, et al. This article should appeal to health insurance payers and policy makers who are in the business of management of hepatitis C infection, especially within health care systems that will not have access immediately to the newer directacting antiviral agents which were reviewed recently in the Annals of Hepatology.1 In this meta-analysis, data were extracted systematically allowing guidance regarding efficacy of treating chronic hepatitis C infection using first generation protease inhibitors (PI): boceprevir and telaprevir, no matter if patients were previously exposed to pegylated interferon plus ribavirin (PR). The results of this study may also assist clinicians the usage of old drugs with better outcomes especially when individualized treatments of hepatitis C genotype 1 are considered. The goal of this systematic analysis was to summarize the world literature for predictors of the primary outcome for sustained viral response (SVR) defined as negative viral load at week 12 or 24.

Palabras clave:

2014-12-22   |   409 visitas   |   Evalua este artículo 0 valoraciones

Vol. 14 Núm.1. Enero-Febrero 2015 Pags. 4-6 Ann Hepatol 2015; 14(1)